随着集采政策深入实施,成熟产品未中选的跨国药企们正加大调整力度以适应市场变化。默沙东中国近日向员工公布了组织架构的最新调整。值得关注的是,默沙东在这轮调整中新设立了企业家事业部(BU),将感染、肿瘤、糖尿病领域的诸多成熟产品归入其中,这些产品大多数已进入集采范围,引起业界关注。整合资源捍卫市场份额据悉,默沙东此番新设的企业家事业部前身是成立于2015年7月的糖尿病事业部(DBU)。彼时,默沙东将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.